| | Create free blog ( Türkçe , Deutsch , Español )
14 "health news" etiketi kullanan gönderi (sayfa 2)"health news" etiketi kullanan diğer içerikler resimler, videolar

Save Money: Try This Healthy Meat Substitute

If you have been thinking about some other forms of protein now that the cost of meat is rising, consider the legumes, a category of vegetable that includes beans, peas, peanuts, soybeans, and lentils.

Legumes may be small but they are packed with nutrition. Health benefits include their high-quality and low-fat protein, their cholesterol-lowering soluble fiber, and their nutrients, such as iron, folate, and other B vitamins. Legumes are also classified as a low-glycemic-index food, meaning that they won't spike your blood glucose levels. Eating lots of legumes has been linked to decreases in one's risks of type 2 diabetes, heart disease, and certain types of cancer.

In the Food Guide Pyramid, legumes are included within the meats and beans group, even though they are a starchy food and contain carbohydrates. One serving of legumes is considered to be a quarter cup of cooked dry beans or peas and is equivalent to 1 ounce of meat. USDA recommendations call for only 5 to 6 ounces from the meats and beans group per day, although needs will vary depending on age, gender and physical activity level. Knowing about these amounts, you can see how we Americans consume too much meat and protein.

So what can you do to add some legumes to your daily diet? First, put them on your grocery list for your next trip to the store. Look for legumes like black, fava, navy, pinto, kidney, or garbanzo beans; lentils; and soybeans. These come dry, canned, frozen or fresh, so look in different sections of the supermarket. These tips will help you add them to your diet.

  • Add beans to salads, soups, stews, or casseroles. Even if a recipe doesn't call for beans, you can often add them anyway.
  • Mix beans or lentils with pasta or rice and skip the meat at that meal.
  • For a sauce, a spread, or a dip, puree legumes and then add spices and garlic — think hummus.
  • Snack on edamame (fresh soybeans) or soynuts instead of crackers and chips.
  • Use legumes as a main course; just add spices and vegetables.

Think about your diet and how you can make small changes for a big impact on your health. What are some of your favorite ways to use legumes?

Is Breakfast the Most Important Meal of the Day?

Don't try to cut calories from your day by skipping breakfast. Recent research from a study conducted in both Venezuela and the U.S. indicates (once again) that breakfast is an important meal.

This study, which included 94 obese women, showed that a big breakfast (610 calories) that included plenty of carbs and protein, when followed by a smaller lunch and an even smaller dinner, resulted in significant weight loss over several months, when compared to a lower-carb diet.

We've known for some time that people who eat breakfast often weigh less than people who skip it. One reason for this is that people who skip breakfast are actually making themselves extra hungry and so are probably going to eat more calories throughout the day. Breakfast can help to control hunger and give you lots of nutrients and energy to start your day.

Another reason behind the weight loss-breakfast connection is that breakfast jump-starts your metabolism. Think of your metabolism as a fire. Overnight, the fire dies back; breakfast is like the wood that gets the flames crackling again. If you don't start up your metabolism early in the day, you won't be burning all the calories that you could be.

While you needn't eat a 600-calorie breakfast every day, you should take away the message that it may still be the day's most important meal. Here are some tips on eating a healthy breakfast

  • It should control cravings and keep you feeling fuller longer.
  • Include some carbohydrates, protein, and healthy fats.
  • If you eat a high-calorie breakfast, then keep your other meals lower in calories.
  • Always try to serve breakfast to your kids — they'll concentrate better at school, have a healthier body weight, and get more needed vitamins and minerals.

Veggies May Protect Women from Diabetes

Diabetes is still on the rise. New numbers confirm that from 2005 to 2007 the total prevalence of diabetes in the U.S. increased by 13.5 percent.

This means that now 8 percent of the total population has diabetes (23.6 million children and adults). In 2007, 1.6 million new cases of diabetes were diagnosed in people aged 20 and older.

Amidst the bad news of these surging numbers, there's good news about prevention from researchers at Tulane University School of Public Health and Tropical Medicine in New Orleans. They found that green leafy vegetables may reduce the risk of type 2 diabetes in women.

For every additional serving of green leafy vegetables a woman eats per day, there was a 9 percent reduction in risk. (Men, feel free to go ahead and up your intake of veggies and fruits, too, even if this study wasn't about you.)

This isn't the first study to show a relationship between a reduction in type 2 diabetes and the eating of more vegetables. Reasons for this reduction in risk may be that vegetables are low in calories and fat and high in antioxidants, fiber, and a variety of vitamins and minerals — all things definitely not associated with an increased risk of diabetes.

The take-home message here should be simply to include vegetables every day in your meals, and then some. Think about planning your meals around what vegetable you are having (in season, I hope) and then adding other foods. When you sit down to eat, vegetables should be covering half your plate.

Whether those vegetables are fresh, frozen, or canned, they are an important part of your diet and may reduce your risk of type 2 diabetes.

Anemia Drugs Linked to Stroke Study Deaths: FDA

FRIDAY, Sept. 26 (HealthDay News) — Preliminary results from a German study suggest that stroke patients’ use of anti-anemia drugs such as Aranesp, Procrit and Epogen might end up boosting their risk for death, the U.S. Food and Drug Administration (FDA) warned on Friday.

The goal of the study was to see if high doses of the anti-anemia drug epoetin alfa could improve the ability of stroke patients to take care of themselves after recovering from a stroke.

The hope was that the drug would be neuroprotective, but use of epoetin alfa now appears linked to a near-doubling of mortality.

This is not the first time that these drugs have come under scrutiny. In the United States, medications like Procrit were marketed heavily as anemia treatments, particularly for cancer patients and those with kidney failure.

However, in July of this year, the FDA called on manufacturers of Aranesp and Procrit to add a warning label that could limit their use for cancer patients.

These changes were spurred by studies that showed these types of medications might cause tumors to spread and also raise patients’ risks for bleeding. These findings resulted in an FDA advisory committee recommending in June that while the drugs should remain on the market, they should not be used in patients whose cancer is curable.

The committee also voted to recommend against the drugs’ use in patients with breast or head and neck cancer.

The new German study looked at the use of epoetin alfa as an aid to stroke recovery.

“These drugs are not licensed in the United States for this particular use,” noted Dr. Kathy Robie-Suh, a team leader in the division of medical imaging and hematology at the Center for Drug Evaluation and Research, part of the FDA’s Office of New Drugs and Office of Drug Safety.

“The drug has been approved for about 19 years for treating anemia in patients with acute renal [kidney] failure and in other settings,” Robie-Suh said. “Today’s warning doesn’t have any bearing on the particular label uses of the product in the United States,” she said.

The FDA will continue to look into the results of this study, Robie-Suh said. “We have asked for more information about the study. We would certainly like to receive the data, but those data are not in our hands or under our control,” she said.

For the trial, 522 stroke patients were randomly assigned to receive relatively high doses of epoetin alfa or a placebo. Some patients were also given R-tPA, a powerful clot-busting drug.

Three months after the start of the trial, 16 percent of the patients who received high doses of the drug epoetin alfa died, compared with 9 percent of patients who were not given the drug, according to the U.S. Food and Drug Administration (FDA).

Among the deaths in the German trial, about 50 percent occurred within the first week after the drug was started. Among those receiving the drug, 4 percent died from bleeding within the brain compared with 1 percent of the patients who were not given the drug.

The FDA said that it expects to receive more data on the study “within the next several weeks,” and when the agency’s analysis is complete, it will “communicate our conclusions and recommendations to the public.”

Friday’s FDA notice was issued after Ortho Biotech — the division of the pharmaceutical giant Johnson and Johnson, which makes Procrit — alerted the agency to the results of the German trial.

“Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke,” the company said in a Sept. 17 statement. “Ortho Biotech has reported this information to the U.S. Food and Drug Administration and to European regulatory authorities. Additional analyses are under way to better understand these preliminary results.”

“This study is interesting, because people were looking at potential neuroprotective effects of erythropoiesis-stimulating agents (ESAs),” said Dr. Samuel M. Silver, a spokesman for the American Society of Hematology.

These patients were not anemic, Silver noted. “They were also receiving very powerful clot-busting drugs at the same time as relatively high doses of ESAs. These are not the typical patients in any way shape or form that usually receive these drugs,” he said.

Silver doesn’t think further action by the FDA is needed. “I don’t think the drug needs to be looked at for patients who are currently being treated in this country, but it certainly will give pause to the way studies are being designed to look at the neuroprotective effects of these drugs,” he said.

More information

For more information on ESA’s, visit the U.S. Food and Drug Administration.

SOURCES: Kathy Robie-Suh, M.D., Ph.D., team leader, Division of Medical Imaging and Hematology, Office of New Drugs and Office of Drug Safety, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Samuel M. Silver, M.D., Ph.D., spokesman, American Society of Hematology; statement, Ortho Biotech, Bridgewater, N.J.

By Steven Reinberg
HealthDay Reporter

Last Updated: Sept. 26, 2008

Ps-Tuts.com Topsites free hit counters by free-counters.netHealth Blogs - Blog Top Sites ToplisteBlogCatalog